27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
NEWARK, Calif., Nov. 14, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet medical need, today announced that management will participate in two investor conferences including the Stifel 2019 Healthcare Conference taking place November 19-20, 2019 in New York City and the Evercore ISI 2nd Annual HEALTHCONx Conference in Boston, MA – December 3-5, 2019.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
| Stifel 2019 Healthcare Conference | |
| Date: | Tuesday, November 19 |
| Time: | 8:00am Eastern Time |
| Webcast: | http://ir.cymabay.com/events |
| Evercore ISI 2nd Annual HEALTHCONx Conference | |
| Date: | Tuesday, December 3 |
| Time: | 11:45am Eastern Time |
| Webcast: | http://ir.cymabay.com/events |
About CymaBay
CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need. CymaBay's lead development candidate, seladelpar, is a potent, selective and orally active PPARδ agonist currently in development for the treatment of patients with primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), and nonalcoholic steatohepatitis (NASH). CymaBay is evaluating seladelpar in a global, Phase 3 registration study in PBC, a Phase 2 dose ranging study in PSC and a Phase 2b dose ranging study in NASH.
Want Private Access to Benzinga Analyst?
Check out the latest strategies our team of experts are using every week so that you can always adapt to the market like the pros!—Get FULL Access to This Week's Webinar Here.
For additional information about CymaBay visit www.cymabay.com.
Contact:
Hans Vitzthum
LifeSci Advisors, LLC
617-430-7578
Hans@LifeSciAdvisors.com
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.